Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05102162 · ClinicalTrials.gov registry record · Phase 4
BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia
A Phase 4 study, sponsored by University of Florida.
- Terminated
- Registry status
- Phase 4
- Development phase
- 35
- Enrollment target
NCT05102162 is a Phase 4 study that was terminated before completion, run by University of Florida. The registered enrollment target is 35 participants.
The verdict
NCT05102162, a Phase 4 study, was terminated before completion, sponsored by University of Florida.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 35 participants
- Enrollment target
Study Summary
The study plans to randomize a total of 240 patients infected with Gram-negative bacterial pneumonia to receive beta-lactam (meropenem, cefepime, or piperacillin/tazobactam) continuous or intermittent infusion and collect baseline and regular follow-up respiratory cultures to assess the development of new resistance. The investigators will measure beta-lactam concentration to assess the impact of drug exposure on the bacterial resistance.
Interventions
- DRUG Cefepime, Meropenem, or Piperacillin/Tazobactam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2021-12-17 |
| Est. Completion | 2023-02-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05102162
The ClinicalTrials.gov registry entry for NCT05102162 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cefepime, Meropenem, or Piperacillin/Tazobactam is the first listed.
NCT05102162 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05102162 about?
NCT05102162 is a clinical study titled "BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia". The study plans to randomize a total of 240 patients infected with Gram-negative bacterial pneumonia to receive beta-lactam (meropenem, cefepime, or piperacillin/tazobactam) continuous or intermittent infusion and collect baseline and regular follow-up respiratory cultures to assess the development ...
What is the current status of trial NCT05102162?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2021-12-17. Estimated completion is 2023-02-28.
What interventions are being tested in trial NCT05102162?
The interventions under investigation include: Cefepime, Meropenem, or Piperacillin/Tazobactam (DRUG).
Who is sponsoring clinical trial NCT05102162?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.